Literature DB >> 12404605

Antidepressants in clinical practice: limitations of assessment methods and drug response.

Sidney H Kennedy1, Beata S Eisfeld, Jeffrey H Meyer, R Michael Bagby.   

Abstract

There is a recognized gap between knowledge derived from 'efficacy' data - based on usually brief randomized controlled trials and findings in natural practice 'effectiveness' studies. In considering the limitations of current antidepressants in clinical practice, we have selected three clinically important issues to examine in a natural practice data base that has been in existence for several years. These relate to: (1) Diagnostic heterogeneity and potential advances using functional brain imaging; (2) Variability of outcome measures during treatment and (3) Time to response and prediction of outcome. Copyright 2001 John Wiley & Sons, Ltd.

Year:  2001        PMID: 12404605     DOI: 10.1002/hup.189

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  10 in total

1.  Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.

Authors:  Boadie W Dunlop; Mary E Kelley; Tanja C Mletzko; Cristina M Velasquez; W Edward Craighead; Helen S Mayberg
Journal:  J Psychiatr Res       Date:  2011-11-26       Impact factor: 4.791

2.  Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.

Authors:  Lev Gertsik; Russell E Poland; Catherine Bresee; Mark Hyman Rapaport
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

Review 3.  Pharmacotherapy to sustain the fully remitted state.

Authors:  Sidney Kennedy; Roger McIntyre; Angelo Fallu; Raymond Lam
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

Review 4.  Psychosocial and clinical predictors of response to pharmacotherapy for depression.

Authors:  R Michael Bagby; Andrew G Ryder; Carolina Cristi
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

5.  The efficacy of acute electroconvulsive therapy in atypical depression.

Authors:  Mustafa M Husain; Shawn M McClintock; A John Rush; Rebecca G Knapp; Max Fink; Teresa A Rummans; Keith Rasmussen; Cynthia Claassen; Georgios Petrides; Melanie M Biggs; Martina Mueller; Shirlene Sampson; Samuel H Bailine; Sarah H Lisanby; Charles H Kellner
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

6.  Reboxetine: a preliminary report on its use through the Special Access Program.

Authors:  Sidney H Kennedy; Raymond W Lam; Nicole L Cohen; Michael Rosenbluth; Stephen T H Sokolov; Roger S McIntyre; Pierre Chue; Gerry Craigen
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

7.  Agomelatine and its therapeutic potential in the depressed patient.

Authors:  Sidney H Kennedy; Beata S Eisfeld
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

8.  Effect of aerobic exercise training on chinese population with mild to moderate depression in Hong Kong.

Authors:  Cassandra W H Ho; S C Chan; J S Wong; W T Cheung; Dicky W S Chung; Titanic F O Lau
Journal:  Rehabil Res Pract       Date:  2014-03-30

Review 9.  Efficacy and tolerability of agomelatine in the treatment of depression.

Authors:  Blanka Kores Plesničar
Journal:  Patient Prefer Adherence       Date:  2014-05-02       Impact factor: 2.711

10.  The Impact of Chronic Mild Stress and Agomelatine Treatment on the Expression Level and Methylation Status of Genes Involved in Tryptophan Catabolic Pathway in PBMCs and Brain Structures.

Authors:  Paulina Wigner; Ewelina Synowiec; Paweł Jóźwiak; Piotr Czarny; Katarzyna Białek; Michal Bijak; Janusz Szemraj; Piotr Gruca; Mariusz Papp; Tomasz Sliwinski
Journal:  Genes (Basel)       Date:  2020-09-18       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.